Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

ween pirfenidone and placebo in the percentage of patients that experienced a serious adverse event (SAE) and the pattern of adverse events (AEs) was, in general, comparable to that observed in previous clinical studies of pirfenidone.
  • InterMune is preparing an NDA for submission to the FDA in the summer of 2009, to be followed by an MAA submission to the European Medicines Agency (EMEA) around the end of 2009.
  • Results from the CAPACITY studies will be presented in an oral late-breaker session at 3:35 p.m. PDT on May 19 at the International Conference of the American Thoracic Society (ATS) in San Diego.

  • ITMN-191:

    • On January 12, InterMune announced top-line results from a 14-day, Phase 1b study of ITMN-191 in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin).
      • After 14 days of triple combination therapy, the median change in HCV RNA from baseline exceeded 5 log10 in five of the six dosage cohorts, and was -5.4 log10 and -5.7 log10 in the best performing q12h and q8h cohorts, respectively. ITMN-191 delivered viral kinetic performance that is comparable to the best results reported to date for other protease inhibitors in similar experiments.
      • There was no evidence of viral rebound during ITMN-191 treatment in any cohort.
      • On April 24, InterMune reported that data from the triple combination study had informed the dose selection for the Phase 2b program of ITMN-191. The Phase 2b trial, expected to begin in the summer of 2009, will study both q12h regimens (600mg and 900mg q12h) and a q8h regimen (300mg q8h) and both 12-week and 24-week treatment durations.

    • At the Annual Meeting of the European Association for the Study of the Liver (EASL
      '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related biology technology :

    1. InterMune to Release First Quarter Financial Results on April 30
    2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
    3. InterMune to Present at Canaccord Adams Hepatitis C Conference
    4. InterMune to Present at Citis 4th Annual Biotech Day
    5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
    6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
    7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
    8. InterMune Announces Issuance of U.S. Patent for ITMN-191
    9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
    10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
    11. InterMune to Present at J.P. Morgan Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/1/2014)... transport of light is the photonic analog of topological ... case, the current flows around the edge of the ... "topological" in that even if electrons encounter impurities in ... losing energy., In the ... regular material but in a meta-material consisting of an ...
    (Date:8/1/2014)... , Aug. 1, 2014 Research ... "The World Market for Flow Cytometry in ... http://photos.prnewswire.com/prnh/20130307/600769 ... are now an important component of advanced IVD ... instruments for cancer diagnostics, but their newer clinical ...
    (Date:8/1/2014)... One of the major revolutions taking place ... is the practice of using genomic and other molecular ... biology. Personalized diagnostics—laboratory analyses that inform the practice of ... future. This fall, AACC ,s first ever ... this exciting field and the novel technologies driving it ...
    (Date:8/1/2014)... 2014 Once a decision has been ... webinar will discuss how to define your tolerance for ... Bob Allen, Senior Director of Facilities Integration at Fluor ... Fluor Industrial Services, and special guest Carrier Li, Director ... Amgen, as they provide an examination of the Conceptual ...
    Breaking Biology Technology:On-chip topological light 2On-chip topological light 3The World Market for Flow Cytometry in IVD Applications 2First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2
    ... Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased ... agreement with Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) ... to Lifeline Biotechnologies for a combination of stock, ... Endoscopy originally purchased the products from Lifeline Biotechnologies ...
    ... plc (LSE: SHP, NASDAQ: SHPGY ) announces ... Court of the Southern District of,New York against Mylan ... for infringement of Shire,s,patent: U.S. Patent No. 5,968,976 (",976 ... filed in response to an Abbreviated New Drug Application,("ANDA") ...
    ... 20 A new, innovative study,shows that a ... plus dexamethasone not only prevents chemotherapy-induced nausea,and vomiting ... oncology,patients. Data presented today at the ESMO Symposium ... New data presented today at ...
    Cached Biology Technology:Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc. 2Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent 2Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent 3Palonosetron Warrants Adequate Caloric Intake in Oncology Patients Receiving High Emetogenic Chemotherapy 2Palonosetron Warrants Adequate Caloric Intake in Oncology Patients Receiving High Emetogenic Chemotherapy 3Palonosetron Warrants Adequate Caloric Intake in Oncology Patients Receiving High Emetogenic Chemotherapy 4
    (Date:7/31/2014)... available in German . ... gases similar to a sponge that soaks up liquids. ... hydrogen or greenhouse gases. However, loading of many MOFs ... Technology (KIT) now report in Nature Communications ... MOF surface. This can be prevented by water-free synthesis ...
    (Date:7/31/2014)... the photovoltaic effect in 1839, humankind has sought to ... its own purposes. In a new research report published ... FASEB Journal , scientists may have uncovered a ... focusing on a naturally occurring combination of lipids that ... over time and across speciessuggests that this specific natural ...
    (Date:7/31/2014)... Professor of Clinical Surgery at LSU Health Sciences Center ... team of plastic and reconstructive surgeons who report a ... select patients for a specific surgical migraine treatment technique. ... surgery to decompress the nerves that trigger migraines experienced ... The study, which confirms the benefit of surgical treatment ...
    Breaking Biology News(10 mins):Free pores for molecule transport 2Scientists shine bright new light on how living things capture energy from the sun 2Surgeons report significant migraine relief from cosmetic eyelid surgery technique 2
    ... disease ever eradicated. In two studies in the Dec. 15 ... scientists are working to ensure that once it is gone, ... immune systems were weakened by HIV would re-introduce poliovirus into ... switching forms of vaccine from a live, attenuated vaccine to ...
    ... for millennia, but there has been great controversy about ... Proceedings of the National Academies of Sciences, a team ... University of Wisconsin-Madison has for the first time demonstrated ... potato. , The scientists analyzed DNA markers in 261 ...
    ... Pumps implanted into the chest to maintain circulation can ... end-stage heart failure who are not candidates for heart ... led by Duke University Medical Center cardiologists. , The ... employed when the heart's left ventricle ?the chamber of ...
    Cached Biology News:Polio vaccination strategies assessed as eradication nears 2Polio vaccination strategies assessed as eradication nears 3Finding rewrites the evolutionary history of the origin of potatoes 2Implantable pumps extend lives of patients too sick for transplant 2Implantable pumps extend lives of patients too sick for transplant 3
    ... Thermo has established an expertise in ... both for solid support synthesis and synthesis ... controlled by Mass Spectrometry and analytical HPLC ... provide products that meet the highest quality ...
    The Wellwash 4 Mk 2 microplate washer combines flexibility, simplicity and ease of use. This reliable microplate washer meets the exacting standards of today's ELISA assay requirements....
    ... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
    ... dispensers save space and organize ... and other garb. They are ... for small parts used in ... acrylic. Many other sizes and ...
    Biology Products: